Prevention of hepatitis B virus-related hepatocellular carcinoma

Kao, Jia‐Horng

doi:10.20517/2394-5079.2020.125

Cited by 14 publications

(13 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 All the other risk models use baseline parameters to do so. 2 We are glad to learn the authors confirm our previous findings that the on-treatment parameters are superior to those at baseline in predicting HCC development, and that platelet count and AFP level at 12 months of treatment are the two most influential ontreatment predictors, which we identified through Cox proportional hazards regression analysis. 3 The authors' statement that their model is the first one to use post-treatment parameters for HCC prediction is incorrect.…”

supporting

confidence: 67%

“…To the best of our knowledge, there have been eight published HCC risk models for CHB patients receiving oral antiviral therapy prior to the present study. 2 Among them, the APA-B, originally proposed by our team, is the only model that uses parameters at 12 months of entecavir treatment, including age, platelet count and AFP level to develop the predictive score. 3 All the other risk models use baseline parameters to do so.…”

mentioning

confidence: 99%

See 1 more Smart Citation

On‐treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B

Peng

Chen

2021

Liver International

View full text Add to dashboard Cite

supporting

confidence: 67%

mentioning

confidence: 99%

On‐treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B

Peng

Chen

2021

Liver International

View full text Add to dashboard Cite

“…Vaccination and anti-viral therapies to inhibit new infections and viral replication of HBV is the first step in preventing the occurrence of HBV-HCC. These strategies are highly efficacious in terms of interrupting the progression from chronic infection to HCC but do not eliminate the risk of HCC development entirely [21][22][23]. Therefore, early detection of HCC in chronic hepatitis B (CHB) patients, effective treatments, and prevention of recurrence are of great importance for further reducing HBV infection-associated mortality.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, early detection of HCC in chronic hepatitis B (CHB) patients, effective treatments, and prevention of recurrence are of great importance for further reducing HBV infection-associated mortality. Currently, several predicting models incorporating clinical features and viral factors (e.g., serum levels of HBV DNA, HBeAg, and HBsAg) have been developed to evaluate the risk of HCC development in CHB patients [21], with periodic screening using ultrasonography with alpha-fetoprotein (AFP) among high-risk groups the most frequently used strategy for early detection of HBV-HCC. However, the sensitivity and specificity of these methods are not satisfactory so far.…”

Section: Introductionmentioning

confidence: 99%

Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1

Liu

2021

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is an important cause of cancer death worldwide, and hepatitis B virus (HBV) infection is a major etiology, particularly in the Asia-Pacific region. Lack of sensitive biomarkers for early diagnosis of HCC and lack of effective therapeutics for patients with advanced HCC are the main reasons for high HCC mortality; these clinical needs are linked to the molecular heterogeneity of hepatocarcinogenesis. Animal models are the basis of preclinical and translational research in HBV-related HCC (HBV-HCC). Recent advances in methodology have allowed the development of several animal models to address various aspects of chronic liver disease, including HCC, which HBV causes in humans. Currently, multiple HBV-HCC animal models, including conventional, hydrodynamics-transfection-based, viral vector-mediated transgenic, and xenograft mice models, as well as the hepadnavirus-infected tree shrew and woodchuck models, are available. This review provides an overview of molecular mechanisms and animal models of HBV-HCC. Additionally, the metastatic tumor antigen 1 (MTA1), a cancer-promoting molecule, was introduced as an example to address the importance of a suitable animal model for studying HBV-related hepatocarcinogenesis.

show abstract

“… 5 , 6 The number of patients with HCC is still increasing, and the prognosis of HCC remains poor due to a lack of effective treatment. 7 It has been reported that the five-year survival rate of advanced-stage HCC is less than 15%, 8 while the five-year survival rate of early-stage HCC is more than 75%. 9 Thus, the medical burden is heavy in terms of patients with HCC, and thus, early diagnosis of HCC is extremely important.…”

Section: Introductionmentioning

confidence: 99%

PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma

Jiang¹,

Song²,

Pan³

et al. 2021

IJGM

View full text Add to dashboard Cite

Objective The occurrence and development of hepatocellular carcinoma (HCC) remain unclear. This study aimed to investigate potential diagnostic or prognostic markers for early HCC by applying bioinformatic analysis. Methods The gene expression profiles of early HCC and normal tissues from a TCGA dataset were used to identify differentially expressed genes (DEGs) and then analysed by weighted gene coexpression network analysis. The integrated genes were selected to construct the protein–protein interaction (PPI) network and determine the hub genes. The prognostic impact of the hub genes was then analysed. Results A total of 508 integrated genes were selected from the 615 DEGs and 8956 genes in the turquoise module. A PPI network was constructed, and the top 20 hub genes, including apolipoprotein A-IV (APOA4), fibrinogen gamma chain (FGG), vitamin K-dependent protein Z (PROZ), secreted phosphoprotein 24 (SPP2) and fetuin-B (FETUB), were identified. Only PROZ was significantly associated with the prognosis of early HCC. Conclusion In this study, we demonstrated that the expression of PROZ was decreased in early HCC compared with normal liver controls, and low PROZ expression might result in poor overall survival of early HCC.

show abstract

Prevention of hepatitis B virus-related hepatocellular carcinoma

Cited by 14 publications

References 121 publications

On‐treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B

On‐treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B

Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1

PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma

Contact Info

Product

Resources

About